帕博利珠单抗或联合化疗对比单纯化疗一线治疗晚期胃癌的III期KEYNOTE-062试验
KEYNOTE-062是一项III期随机对照试验,纳入763例初治晚期胃/胃食管结合部癌且PD-L1 CPS≥1的患者,随机接受帕博利珠单抗、帕博利珠单抗联合化疗或单纯化疗。帕博利珠单抗单药在CPS≥1人群的总生存不劣于化疗,且不良反应更少;但帕博利珠单抗单药或联合化疗均未在测试终点上优于化疗。
要点
- 帕博利珠单抗单药在PD-L1 CPS≥1患者中OS非劣于化疗,3-5级治疗相关不良事件率更低。
- 帕博利珠单抗单药或联合化疗在CPS≥1和CPS≥10人群的OS/PFS均未显著优于化疗。
- 帕博利珠单抗联合化疗的3-5级治疗相关不良事件率高达73%。
核心结论
- 在初治晚期胃/胃食管结合部癌患者中,帕博利珠单抗单药对比化疗在PD-L1 CPS≥1人群的OS非劣效,且不良反应更少。
- 帕博利珠单抗单药或帕博利珠单抗联合化疗在测试的OS和PFS终点上均未优于单纯化疗。
研究设计与样本
- III期KEYNOTE-062随机、对照、部分盲法干预试验,2015年9月18日至2017年5月26日从29个国家200个中心入组763例初治局部晚期不可切除或转移性胃/胃食管结合部癌且PD-L1 CPS≥1患者。
- 患者按1:1:1随机接受帕博利珠单抗200 mg、帕博利珠单抗联合化疗(顺铂80 mg/m2/d第1天+氟尿嘧啶800 mg/m2/d第1至5天或卡培他滨1000 mg/m2每日两次)或化疗联合安慰剂,每3周一次。
主要发现
- 中位随访29.4个月(范围22.0-41.3),帕博利珠单抗对比化疗在CPS≥1人群的OS中位值为10.6 vs 11.1个月(HR 0.91,99.2%CI 0.69-1.18),达到非劣效。
- 帕博利珠单抗单药在CPS≥1人群未优于化疗;在CPS≥10人群OS中位值为17.4 vs 10.8个月(HR 0.69,95%CI 0.49-0.97),但该差异未进行统计学检验。
- 帕博利珠单抗、帕博利珠单抗联合化疗和化疗的3-5级治疗相关不良事件率分别为17%、73%和69%。
临床怎么用
- 对于PD-L1 CPS≥1的初治晚期胃/胃食管结合部癌患者,帕博利珠单抗单药可作为化疗的替代选择之一,尤其关注其较低的不良事件率。
- 帕博利珠单抗联合化疗在该试验中未显示优于化疗,临床决策需结合患者具体情况和后续证据。
局限性
- CPS≥10人群的OS差异未进行统计学检验,不能据此得出优效性结论。
- 该试验未报告其他亚组或生物标志物分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ cancer with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater. DESIGN, SETTING, AND PARTICIPANTS: The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional trial enrolled 763 patients with untreated, locally advanced/unresectable or metastatic G/GEJ cancer with PD-L1 CPS of 1 or greater from 200 centers in 29 countries between September 18, 2015, and May 26, 2017. INTERVENTIONS: Patients were randomized 1:1:1 to pembrolizumab 200 mg, pembrolizumab plus chemotherapy (cisplatin 80 mg/m2/d on day 1 plus fluorouracil 800 mg/m2/d on days 1 to 5 or capecitabine 1000 mg/m2 twice daily), or chemotherapy plus placebo, every 3 weeks. MAIN OUTCOMES AND MEASURES: Primary end points were overall survival (OS) and progression-free survival (PFS) in patients with PD-L1 CPS of 1 or greater or 10 or greater. RESULTS: A total of 763 patients were randomized to pembrolizumab (n = 256), pembrolizumab plus chemotherapy (n = 257), or chemotherapy (n = 250). The median (range) age of all patients in the study cohort was 62 (20-87) years; 554 of 763 (72.6%) were men. At final analysis, after a median (range) follow-up of 29.4 (22.0-41.3) months, pembrolizumab was noninferior to chemotherapy for OS in patients with CPS of 1 or greater (median, 10.6 vs 11.1 months; hazard ratio [HR], 0.91; 99.2% CI, 0.69-1.18). Pembrolizumab monotherapy was not superior to chemotherapy in patients with CPS of 1 or greater. Pembrolizumab prolonged OS vs chemotherapy in patients with CPS of 10 or greater (median, 17.4 vs 10.8 months; HR, 0.69; 95% CI, 0.49-0.97), but this difference was not statistically tested. Pembrolizumab plus chemotherapy was not superior to chemotherapy for OS in patients with CPS of 1 or greater (12.5 vs 11.1 months; HR, 0.85; 95% CI, 0.70-1.03; P = .05) or CPS of 10 or greater (12.3 vs 10.8 months; HR, 0.85; 95% CI, 0.62-1.17; P = .16) or for PFS in patients with CPS of 1 or greater (6.9 vs 6.4 months; HR, 0.84; 95% CI, 0.70-1.02; P = .04). Grade 3 to 5 treatment-related adverse event rates for pembrolizumab, pembrolizumab plus chemotherapy, and chemotherapy were 17%, 73%, and 69%, respectively. CONCLUSIONS AND RELEVANCE: This phase 3 randomized clinical trial found that among patients with untreated, advanced G/GEJ cancer, pembrolizumab was noninferior to chemotherapy, with fewer adverse events observed. Pembrolizumab or pembrolizumab plus chemotherapy was not superior to chemotherapy for the OS and PFS end points tested. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02494583.
引用
- Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32880601. doi:10.1001/jamaoncol.2020.3370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。